Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2870)	6/2/2010 9:22:15 AM
From: mlkr	Read Replies (1) \| Respond to of 3722

Bernard; thnx .. I thought you would never respond to my inquiries! I was wrong.. keep up with good work here!

To: Jibacoa who wrote (2870)	6/16/2010 10:58:43 AM
From: Jibacoa	Respond to of 3722

NBIX opened with an UG and was up 18.29% but is up only 10% at presnt.<g> Volume is almost 4x its ADV bigcharts.marketwatch.com It announced early this morning that it will host a C.C. to report on the global agreement with ABT for the worldwide development n of elagolix and the next-generation GnRH antagonists. The C.C. took place at 8:45am As previously mentioned, the open label extension portion of the Elagolix trial is proceeding well and it seems to have good potential for treatment of dysmenorrhea in patients with endometriosis. The ACTAY is $5.58 But with some good news and a better general market, the stock could double from present levels.<g> bigcharts.marketwatch.com Bernard